Department of Vascular Surgery, Renji Hospital, Shanghai Jiao Tong University College of Medicine, Shanghai 200001, China.
Chin Med J (Engl). 2012 May;125(10):1767-71.
Endovascular recanalization (EVR) is becoming the primary therapy for patients with central venous (brachiocephalic, subclavian, and superior vena cava) occlusion (CVO) caused by benign etiology. In this study, we retrospectively analyzed our experience in using EVR to treat benign CVO in 10 patients between April 2005 and September 2010.
The mean age of the patients was 65.3 years, 2/10 cases were female, and the origin of cause of CVO in 7/10 cases was the hemodialysis access in the upper extremity. The patients were treated with primary stent placement and evaluated with immediate technical success rate and post-interventional patency rate after the procedure.
Eight patients were treated successfully with stent placement and experienced symptomatic relief immediately. No technical complications were observed during EVR treatment. Patients were followed up by ultrasonography and venography. Median follow-up was 13 months. Three patients required secondary procedures to maintain patency.
EVR is an effective and safe treatment in patients with benign CVO. It provides immediate symptom relief and maintains a continuous access for hemodialysis.
血管内再通术（EVR）正成为治疗由良性病因引起的中心静脉（头臂静脉、锁骨下静脉和上腔静脉）阻塞（CVO）的主要疗法。在这项研究中，我们回顾性分析了 2005 年 4 月至 2010 年 9 月期间 10 例使用 EVR 治疗良性 CVO 的经验。
患者的平均年龄为 65.3 岁，2/10 例为女性，7/10 例 CVO 的病因是上肢血液透析通路。对患者进行初次支架置入，并评估术后即刻技术成功率和介入后通畅率。
8 例患者成功接受支架置入治疗，症状立即得到缓解。EVR 治疗过程中未观察到技术并发症。通过超声和静脉造影对患者进行随访。中位随访时间为 13 个月。3 例患者需要进行二次手术以保持通畅。
EVR 是治疗良性 CVO 的有效且安全的方法。它可立即缓解症状，并为血液透析提供持续的通路。
